Design and synthesis of 2-amino-pyrazolopyridines as Polo-like kinase 1 inhibitors.
Fucini, R.V., Hanan, E.J., Romanowski, M.J., Elling, R.A., Lew, W., Barr, K.J., Zhu, J., Yoburn, J.C., Liu, Y., Fahr, B.T., Fan, J., Lu, Y., Pham, P., Choong, I.C., VanderPorten, E.C., Bui, M., Purkey, H.E., Evanchik, M.J., Yang, W.(2008) Bioorg Med Chem Lett 18: 5648-5652
- PubMed: 18793847
- DOI: https://doi.org/10.1016/j.bmcl.2008.08.095
- Primary Citation of Related Structures:
3DBC, 3DBD, 3DBE, 3DBF - PubMed Abstract:
A series of 2-amino-pyrazolopyridines was designed and synthesized as Polo-like kinase (Plk) inhibitors based on a low micromolar hit. The SAR was developed to provide compounds exhibiting low nanomolar inhibitory activity of Plk1; the phenotype of treated cells is consistent with Plk1 inhibition. A co-crystal structure of one of these compounds with zPlk1 confirms an ATP-competitive binding mode.
Organizational Affiliation:
Department of Biology, Sunesis Pharmaceuticals, Inc., 395 Oyster Point Boulevard Suite 400, South San Francisco, CA 94080, USA. rfucini@sunesis.com